Tags

Type your tag names separated by a space and hit enter

Parkinson's disease: drug therapy.
Baillieres Clin Neurol. 1997 Apr; 6(1):89-108.BC

Abstract

Unlike the situation in patients with most other degenerative neurological disorders, individuals with Parkinson's disease (PD) and their physicians have a wide range of effective symptomatic drugs at their disposal. All have somewhat differing indications, potencies and side-effects, and treatment needs to be individualized and also altered as the disease and the duration of drug treatment progress and the patient ages. The main problem for most patients after prolonged treatment with L-dopa is the longterm L-dopa syndrome. Fluctuations and dyskinesias are usually the principal complaint in younger, and neuropsychiatric symptoms in older, patients. Although L-dopa is the 'gold standard' in terms of efficacy, these treatment-related problems make it necessary to regularly monitor patients' response to treatment and if necessary to modify their drug regime accordingly and, particularly in younger patients, to devise treatment strategies whereby the use of L-dopa can be limited or delayed. Currently available alternative or adjunctive treatments to L-dopa preparations include oral dopamine agonists, subcutaneous apomorphine, amantadine, selegiline and anticholinergics, and some guidelines about how and when to use all of these drugs or classes of drugs are presented in this chapter. Despite initial claims of neuroprotection by selegiline, we are still awaiting the more promising second era of drug treatment for PD, whereby hopefully we can retard, halt or prevent the disease itself.

Authors+Show Affiliations

Philipps-Universität Marburg, Klinik für Neurologie, Zentrum für Nervenheilkunde, Germany.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9426870

Citation

Oertel, W H., and N P. Quinn. "Parkinson's Disease: Drug Therapy." Bailliere's Clinical Neurology, vol. 6, no. 1, 1997, pp. 89-108.
Oertel WH, Quinn NP. Parkinson's disease: drug therapy. Baillieres Clin Neurol. 1997;6(1):89-108.
Oertel, W. H., & Quinn, N. P. (1997). Parkinson's disease: drug therapy. Bailliere's Clinical Neurology, 6(1), 89-108.
Oertel WH, Quinn NP. Parkinson's Disease: Drug Therapy. Baillieres Clin Neurol. 1997;6(1):89-108. PubMed PMID: 9426870.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Parkinson's disease: drug therapy. AU - Oertel,W H, AU - Quinn,N P, PY - 1997/4/1/pubmed PY - 1998/1/14/medline PY - 1997/4/1/entrez SP - 89 EP - 108 JF - Bailliere's clinical neurology JO - Baillieres Clin Neurol VL - 6 IS - 1 N2 - Unlike the situation in patients with most other degenerative neurological disorders, individuals with Parkinson's disease (PD) and their physicians have a wide range of effective symptomatic drugs at their disposal. All have somewhat differing indications, potencies and side-effects, and treatment needs to be individualized and also altered as the disease and the duration of drug treatment progress and the patient ages. The main problem for most patients after prolonged treatment with L-dopa is the longterm L-dopa syndrome. Fluctuations and dyskinesias are usually the principal complaint in younger, and neuropsychiatric symptoms in older, patients. Although L-dopa is the 'gold standard' in terms of efficacy, these treatment-related problems make it necessary to regularly monitor patients' response to treatment and if necessary to modify their drug regime accordingly and, particularly in younger patients, to devise treatment strategies whereby the use of L-dopa can be limited or delayed. Currently available alternative or adjunctive treatments to L-dopa preparations include oral dopamine agonists, subcutaneous apomorphine, amantadine, selegiline and anticholinergics, and some guidelines about how and when to use all of these drugs or classes of drugs are presented in this chapter. Despite initial claims of neuroprotection by selegiline, we are still awaiting the more promising second era of drug treatment for PD, whereby hopefully we can retard, halt or prevent the disease itself. SN - 0961-0421 UR - https://www.unboundmedicine.com/medline/citation/9426870/Parkinson's_disease:_drug_therapy_ DB - PRIME DP - Unbound Medicine ER -